摘要
Abstract
Objective:To explore the effect of Ticagrelor of novel antiplatelet drug and Aspirin in secondary prevention of cerebral infarction.Method:A total of 124 patients with cerebral infarction admitted to Department of Neurology,Zhongxiang People's Hospital from March 2020 to January 2022 were selected and divided into experimental group(n=62)and control group(n=62)according to random envelope method.The control group was treated with Aspirin,and the experimental group was treated with a novel antiplatelet drug of Ticagrelor.Cognition and limb function,platelet aggregation rate,cerebral blood perfusion parameters and recurrence were compared between the two groups.Result:After 6 months of treatment,the scores of mini-mental state examination(MMSE)and Fugl-Meyer assessment(FMA)increased in both groups,the platelet aggregation rate at 1 and 5 min decreased,and the scores of MMSE and FMA in the experimental group were higher than those in the control group,the platelet aggregation rate at 1 and 5 min were lower than those in control group(P<0.05).After 6 months of treatment,total cerebral blood flow increased,blood flow velocity of middle cerebral artery(MCA)accelerated and the average passage time shortened in both groups,and total cerebral blood flow in experimental group was greater than that in control group,blood flow velocity of MCA was faster than that in control group,and the average passage time was shorter than that in control group(P<0.05).The recurrence rate of experimental group was 6.45%,which was lower than 19.35%of control group(P<0.05).Conclusion:In secondary prevention of cerebral infarction,Ticagrelor has a significant effect,which can significantly reduce the platelet aggregation rate,improve cerebral blood perfusion,improve cognition and limb function of patients,and prevent cerebral infarction recurrence.关键词
替格瑞洛/二级预防/阿司匹林/脑梗死/新型抗血小板药物Key words
Ticagrelor/Secondary prevention/Aspirin/Cerebral infarction/Novel antiplatelet drug
